GPX4 and neoplasm: This approach adeptly circumvents erastin resistance through the targeted downregulation of the antioxidase GPX4 and the upregulation of the tumor suppressor hypermethylated in cancer 1, precisely exploiting the metabolic susceptibilities of these cancerous cells [39].